Paragonix Technologies announced the PancreasPak Organ Preservation System, an FDA-cleared device designed to protect and monitor donor pancreases during transportation.
The PancreasPak System relies on the principles of Paragonix’s SherpaPak Cardiac Transport System. By establishing a controlled environment, the preservation digitally monitors the pancreas at an optimal thermal range of 4-8°C for up to 21 hours. This recommended temperature standard follows the footsteps of the SherpaPak, which has been shown to safely extend ischemic times, minimize post-transplant outcomes, and improve 2-year patient survival.
The pancreas, unlike other solid organs, is extremely delicate and vulnerable to damage during transport. Traditional methods involving plastic coolers and crushed ice expose the organ to harmful freezing temperatures.
“This is an incredibly exciting time for pancreas transplantation. Preservation impacts organ function, and better preservation would allow us to help more patients. Until now, there has been a distinct lack of innovation within the pancreatic market specifically,” said Dr. Joseph Scalea, Vice Chair of Innovation, Department of Surgery, from Medical University of South Carolina. “An advanced preservation device has the potential to change everything. In just a few short months, we will finally have a tool tailored specifically to our needs, that aligns with our goal to substantially enhance organ viability and patient outcomes.”
“Our team is thrilled to introduce this advanced technology to the pancreatic transplant community,” said Dr. Lisa Anderson, CEO and President of Paragonix. “This milestone demonstrates our dedication to advancing the boundaries of organ transplantation excellence. We are honored to stand at the forefront of preservation and provide unparalleled support to countless patients in need of a heart, lung, liver, and now, pancreas. To be at the forefront and be the first company to provide pancreas preservation technology is a tremendous achievement and consistent with our commitment to service all transplant and donor patients.“
PancreasPak, which has already received FDA 510(k) clearance, will be available for commercial pre-order starting in late June.
